A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation
Astellas Pharma Inc
Astellas Pharma Inc
Thomas Jefferson University
University of Pittsburgh
Medical College of Wisconsin
Wake Forest University Health Sciences
Arog Pharmaceuticals, Inc.
Arog Pharmaceuticals, Inc.
Thomas Jefferson University
Fred Hutchinson Cancer Center
University of Washington
Ohio State University Comprehensive Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
New York Medical College
The University of Hong Kong
Sumitomo Pharma Co., Ltd.
University of Washington
University of Washington
Children's Oncology Group
University of Chicago
Massachusetts General Hospital
University of Chicago
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
University of Maryland, Baltimore
GlycoMimetics Incorporated
Fred Hutchinson Cancer Center
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
Wake Forest University Health Sciences
Dartmouth-Hitchcock Medical Center
Ludwig-Maximilians - University of Munich
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Ulm
Washington University School of Medicine
Washington University School of Medicine
Teva Branded Pharmaceutical Products R&D, Inc.
Ohio State University Comprehensive Cancer Center
Massachusetts General Hospital
Case Comprehensive Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Chicago
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
St. Jude Children's Research Hospital
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and Treatment of Cancer - EORTC